Third Harmonic Bio (THRD) Q2 2024 earnings summary

Executive summary

• Clinical-stage biopharma focused on oral KIT inhibitors for inflammatory diseases, with lead candidate THB335 in Phase 1 trials for chronic spontaneous urticaria and planned expansion into other mast cell-mediated disorders.

• Phase 1 SAD/MAD clinical trial of THB335 is progressing, with results expected in Q1 2025 and preparations underway for Phase 2.

• No products approved or revenue from product sales to date; operations funded by IPO and preferred stock sales.

Financial highlights

• Net loss for Q2 2024 was $10.7 million, up from $7.6 million in Q2 2023; net loss for the six months ended June 30, 2024 was $18.6 million, up from $16.6 million year-over-year.

• Research and development expenses rose to $8.4 million for Q2 2024 from $5.3 million in Q2 2023, mainly due to increased spend on THB335.

• General and administrative expenses increased to $5.7 million in Q2 2024 from $5.4 million in Q2 2023, driven by personnel-related costs and executive recruiting.

• Cash and cash equivalents totaled $255.3 million as of June 30, 2024, expected to fund operations through at least 2026.

• Interest income increased to $3.4 million in Q2 2024, reflecting higher balances and rates.

Outlook and guidance

• Clinical results from the ongoing Phase 1 trial of THB335 are expected in Q1 2025, with rapid progression planned into Phase 2 and expansion into additional indications.

• Existing cash and cash equivalents expected to fund operations and capital expenses through at least 2026.

• Anticipates continued operating losses and increased expenses as clinical development progresses.

• Substantial additional funding will be needed for future growth and commercialization efforts.